奈米颗粒契约製造服务市场－全球产业规模、份额、趋势、机会及预测（按类型、应用、製造能力、最终用户、地区和竞争格局划分，2021-2031年）

全球奈米颗粒契约製造服务市场预计将从 2025 年的 34.2 亿美元成长到 2031 年的 51.7 亿美元，复合年增长率为 7.13%。

该板块专注于奈米级递送机制（例如脂质体和脂质奈米颗粒）的外包生产，这些机制对于药物标靶化和提高稳定性至关重要。市场成长趋势的主要驱动力是基因治疗和肿瘤治疗日益复杂，这促使製药开发商更依赖专业的外部合作伙伴，而不是建立内部能力。产业强劲的发展势头进一步加剧了这种依赖性：根据美国药品研究与製造商协会 (PhRMA) 预测，到 2024 年，将有超过 8000 种药物进入临床开发阶段，从而持续推动对先进製造解决方案的需求。

儘管前景乐观，但该行业在化学、製造和品管(CMC) 合规性方面仍面临诸多挑战。奈米颗粒复杂的物理化学性质为实现一致的表征和规模化生产带来了挑战，常常导致监管核准流程出现瓶颈。这些技术难题需要先进的分析能力，这限制了合格供应商的选择，并增加了创新者的研发成本。因此，满足这些严格的合规要求构成了一大障碍，可能会阻碍这些专业服务的快速扩张和规模化发展。

市场驱动因素

基因治疗和mRNA研发管线的快速发展是全球奈米颗粒契约製造服务市场的主要驱动力。随着这些先进治疗方法从研究阶段迈向商业化，对确保有效细胞内递送的脂质奈米颗粒（LNP）的需求迅速增长，相应的，对专业化生产能力的需求也随之增加。这一趋势得到了大量资本投资的支持；截至2025年12月，再生医学联盟报告称，2024年细胞和基因治疗领域的投资额达到152亿美元。如此强劲的资本支持正在推动各种需要高品质奈米製剂的临床研究。赢创公司在2025年9月预测，到2032年，脂质奈米颗粒市场规模将达到23亿美元，进一步凸显了其长期商业性潜力。

同时，复杂奈米颗粒製剂外包的趋势日益增长，从根本上改变了市场结构。聚合物和脂质奈米颗粒的合成涉及复杂的物理化学过程，需要精确控制其稳定性和粒径，而这些专业技术对于製药创新企业而言往往过于耗费资源，难以在内部维持。因此，企业通常选择与合约研发生产机构 (CDMO) 合作，以利用其监管知识和专业基础设施。领先供应商强劲的财务业绩也印证了这种向外部生产转变的成功。据 Reseepharm 公司称，该公司于 2025 年 3 月宣布，2024 财年销售额创下 8.27 亿欧元的纪录，较上年增长 7%，这主要得益于对综合生产和研发服务的持续需求。

市场挑战

严格的化学、製造和控制 (CMC) 法规对奈米颗粒的生产构成重大障碍，阻碍了全球奈米颗粒契约製造服务市场的扩张。奈米颗粒具有复杂的物理化学性质，例如表面电荷、粒径分布和包封率，这些性质在从实验室规模原型过渡到商业化批量生产时极难控制。这种不可预测性导致生产过程中的变异性，使得合约研发生产机构 (CDMO) 难以满足监管机构要求的严格品质标准，从而导致产品上市延迟。

因此，这些技术执行上的失败会导致研发週期延长，在开发产品的失败率更高。由于缺乏表征数据而导致的计划延期和被拒，使创新者面临巨大的财务风险，并大幅减少了能够转化为盈利商业生产合约的可行专案数量。近期产业数据也印证了这一严峻情况：根据生物技术与创新组织（BIO）的数据显示，2024年在临床实验药物的临床开发成功率降至历史新低，仅6.7%。这一下降主要归因于现代治疗方法的日益复杂化。如此高的失败率严重限制了可用于外包生产的已已通过核准产品的供应，阻碍了其快速市场扩充性。

市场趋势

随着製药公司寻求简化复杂的供应链，整合、端到端的CDMO服务模式的转变正在改变市场格局。传统上，脂质奈米颗粒的生产需要与多家供应商协调，分别负责活性成分的生产、脂质合成、颗粒组装以及填充和包装，这导致技术转移延迟和物流风险。为了应对这些挑战，服务供应商正在提供整合这些关键流程的综合解决方案，从而有效缩短先进疗法的研发週期。这些业务部门的显着财务规模也反映了向全面服务整合的策略转变。根据龙沙集团于2025年5月发布的“2024年更新比较财务业绩”，其涵盖端到端模式的一体化生物製剂平台预计将创造28.8亿瑞士法郎的销售额，凸显了市场对一体化生产合作伙伴的强劲需求。

同时，为满足日益增加的复杂生物药物研发管线的需求，无机和聚合物奈米载体系统的产能扩张正在加速。随着mRNA疫苗和基因疗法的临床应用不断扩展，契约製造正大力投资于专用基础设施，以实现这些先进递送载体的大规模生产。这些资本投资旨在增强技术能力和物理产能，以应对下一代奈米药物复杂的物理化学要求。这一趋势在近期的基础设施建设中得到了充分体现。在CordenPharma于2025年10月发表的一篇题为「CDMO主要平台投资」的报导中，该公司详细介绍了其设施扩建计划，计划新增约900平方公尺符合GMP标准的生产空间，专门用于生产脂质奈米颗粒和其他非病毒载体。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

5. 全球奈米颗粒契约製造服务市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 按类型（脂质、金属、其他）
  • 依用途（治疗药物、诊断药物等）
  • 依生产规模（临床前、临床、商业化）
  • 依最终用户（製药/生技公司、学术/研究机构、其他）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美奈米颗粒契约製造服务市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲奈米颗粒契约製造服务市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区奈米颗粒契约製造服务市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲奈米颗粒契约製造服务市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲奈米颗粒契约製造服务市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球奈米颗粒契约製造服务市场：SWOT分析

第十四章 波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Catalent
• Lonza
• Evonik
• Particle Sciences
• Precision NanoSystems
• CordenPharma
• WuXi AppTec
• Novasep
• Formulaction
• Curia

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Nanoparticle Contract Manufacturing Services Market is projected to expand from USD 3.42 Billion in 2025 to USD 5.17 Billion by 2031, reflecting a CAGR of 7.13%. This sector focuses on the outsourced creation of nanoscale delivery mechanisms, including liposomes and lipid nanoparticles, which are essential for improving drug targeting and stability. The market's upward momentum is largely fueled by the growing intricacy of gene therapy and oncology treatments, which prompts pharmaceutical developers to rely on the specialized facilities of external partners rather than building internal capabilities. This dependency is highlighted by significant industry momentum; according to PhRMA, more than 8,000 medicines were in clinical development during 2024, generating continuous demand for sophisticated manufacturing solutions.

Despite this favorable outlook, the industry faces substantial hurdles related to Chemistry, Manufacturing, and Controls (CMC) compliance. The intricate physicochemical nature of nanoparticles creates challenges in achieving consistent characterization and scale-up, frequently leading to bottlenecks in the regulatory approval timeline. These technical difficulties require advanced analytical capabilities, which limits the pool of qualified vendors and drives up development expenses for innovators. As a result, meeting these stringent compliance requirements stands as a critical barrier that could potentially hinder the rapid expansion and scalability of these specialized services.

Market Driver

The surging growth of gene therapy and mRNA pipelines acts as a major engine for the Global Nanoparticle Contract Manufacturing Services Market. As these cutting-edge modalities progress from research phases to commercialization, the necessity for lipid nanoparticles (LNPs) to ensure effective intracellular delivery has escalated, triggering a simultaneous rise in the need for specialized manufacturing capabilities. This trend is supported by substantial financial investment; the Alliance for Regenerative Medicine reported that investments in the cell and gene therapy sector reached $15.2 billion for the year 2024 as of December 2025. Such strong capital support fuels a wide range of clinical initiatives requiring premium nanoscale formulations, with long-term commercial promise further emphasized by Evonik's September 2025 estimate that the lipid nanoparticle market will hit US$2.3 billion by 2032.

Simultaneously, the increasing tendency to outsource complex nanoparticle formulations is fundamentally altering market mechanics. Synthesizing polymeric and lipid nanoparticles involves elaborate physicochemical procedures demanding exact control over stability and particle size, competencies that are often too resource-heavy for pharmaceutical innovators to sustain internally. Consequently, organizations are frequently allying with Contract Development and Manufacturing Organizations (CDMOs) to utilize their regulatory knowledge and specialized infrastructure. The success of this shift toward external production is demonstrated by the robust financial results of top providers; according to Recipharm, the company announced a record revenue of €827 million for 2024 in March 2025, marking a 7% annual increase fueled by sustained demand for its comprehensive manufacturing and development services.

Market Challenge

Strict Chemistry, Manufacturing, and Controls (CMC) regulations overseeing nanoparticle production represent a significant obstacle to the Global Nanoparticle Contract Manufacturing Services Market's expansion. Nanoparticles exhibit complex physicochemical properties-such as surface charge, size distribution, and encapsulation efficiency-that are exceptionally hard to regulate when moving from lab-scale prototypes to commercial batches. This lack of predictability often results in manufacturing variations, making it difficult for CDMOs to adhere to the rigorous quality benchmarks mandated by regulatory agencies, which in turn stalls product release.

As a result, these failures in technical execution lead to prolonged development schedules and higher failure rates for pipeline assets. Innovators encounter considerable financial jeopardy as projects suffer delays or rejections stemming from insufficient characterization data, effectively shrinking the number of viable programs that graduate to profitable commercial manufacturing agreements. This arduous landscape is highlighted by recent industry data; according to the Biotechnology Innovation Organization, the overall clinical development success rate for investigational drugs fell to a historic low of just 6.7% in 2024, a decline largely attributed to the growing complexity of modern therapies. Such elevated attrition rates critically restrict the supply of approved products ready for outsourced production, thereby obstructing the market's rapid scalability.

Market Trends

The shift toward Integrated End-to-End CDMO Service Models is transforming the market landscape as pharmaceutical companies increasingly look to simplify complex supply chains. Traditionally, producing lipid nanoparticles involved coordinating with various vendors for payload manufacturing, lipid synthesis, particle assembly, and fill-finish, a process that created significant technical transfer delays and logistical liabilities. In response, service providers are combining these essential stages into unified offerings, effectively accelerating development timelines for advanced therapeutics. The strategic move toward holistic service integration is evidenced by the massive financial scale of these divisions; according to Lonza Group's 'Updated Comparative Financial Results for 2024' released in May 2025, their Integrated Biologics platform, covering end-to-end modalities, recorded sales of CHF 2.88 billion, highlighting the strong demand for consolidated manufacturing partners.

At the same time, the expansion of capabilities for inorganic and polymeric nanocarrier systems is speeding up to meet the growing pipeline of complex biologic drugs. As the clinical use of mRNA vaccines and gene therapies broadens, contract manufacturers are heavily investing in specialized infrastructure to facilitate the high-volume production of these sophisticated delivery vectors. These capital injections are aimed at boosting technical competencies and physical capacity to manage the complex physicochemical demands of next-generation nanomedicines. This trend is illustrated by recent infrastructure upgrades; according to a CordenPharma article titled 'CDMO Key Platform Investment' from October 2025, the firm detailed a facility expansion adding roughly 900 square meters of GMP-compliant space specifically for manufacturing lipid nanoparticles and other non-viral vectors.

Key Market Players

• Catalent
• Lonza
• Evonik
• Particle Sciences
• Precision NanoSystems
• CordenPharma
• WuXi AppTec
• Novasep
• Formulaction
• Curia

Report Scope

In this report, the Global Nanoparticle Contract Manufacturing Services Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Nanoparticle Contract Manufacturing Services Market, By Type

• Lipid
• Metal
• Others

Nanoparticle Contract Manufacturing Services Market, By Application

• Therapeutics
• Diagnostics
• Others

Nanoparticle Contract Manufacturing Services Market, By Manufacturing Scale

• Pre-clinical
• Clinical
• Commercial

Nanoparticle Contract Manufacturing Services Market, By End User

• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Others

Nanoparticle Contract Manufacturing Services Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Nanoparticle Contract Manufacturing Services Market.

Available Customizations:

Global Nanoparticle Contract Manufacturing Services Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Nanoparticle Contract Manufacturing Services Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Lipid, Metal, Others)
  • 5.2.2. By Application (Therapeutics, Diagnostics, Others)
  • 5.2.3. By Manufacturing Scale (Pre-clinical, Clinical, Commercial)
  • 5.2.4. By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Nanoparticle Contract Manufacturing Services Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Application
  • 6.2.3. By Manufacturing Scale
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Nanoparticle Contract Manufacturing Services Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By Manufacturing Scale
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Nanoparticle Contract Manufacturing Services Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By Manufacturing Scale
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Nanoparticle Contract Manufacturing Services Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By Manufacturing Scale
      • 6.3.3.2.4. By End User

7. Europe Nanoparticle Contract Manufacturing Services Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Application
  • 7.2.3. By Manufacturing Scale
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Nanoparticle Contract Manufacturing Services Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By Manufacturing Scale
      • 7.3.1.2.4. By End User
  • 7.3.2. France Nanoparticle Contract Manufacturing Services Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By Manufacturing Scale
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Nanoparticle Contract Manufacturing Services Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By Manufacturing Scale
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Nanoparticle Contract Manufacturing Services Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By Manufacturing Scale
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Nanoparticle Contract Manufacturing Services Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By Manufacturing Scale
      • 7.3.5.2.4. By End User

8. Asia Pacific Nanoparticle Contract Manufacturing Services Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Application
  • 8.2.3. By Manufacturing Scale
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Nanoparticle Contract Manufacturing Services Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By Manufacturing Scale
      • 8.3.1.2.4. By End User
  • 8.3.2. India Nanoparticle Contract Manufacturing Services Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By Manufacturing Scale
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Nanoparticle Contract Manufacturing Services Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By Manufacturing Scale
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Nanoparticle Contract Manufacturing Services Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By Manufacturing Scale
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Nanoparticle Contract Manufacturing Services Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By Manufacturing Scale
      • 8.3.5.2.4. By End User

9. Middle East & Africa Nanoparticle Contract Manufacturing Services Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Application
  • 9.2.3. By Manufacturing Scale
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Nanoparticle Contract Manufacturing Services Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By Manufacturing Scale
      • 9.3.1.2.4. By End User
  • 9.3.2. UAE Nanoparticle Contract Manufacturing Services Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By Manufacturing Scale
      • 9.3.2.2.4. By End User
  • 9.3.3. South Africa Nanoparticle Contract Manufacturing Services Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By Manufacturing Scale
      • 9.3.3.2.4. By End User

10. South America Nanoparticle Contract Manufacturing Services Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Application
  • 10.2.3. By Manufacturing Scale
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Nanoparticle Contract Manufacturing Services Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By Manufacturing Scale
      • 10.3.1.2.4. By End User
  • 10.3.2. Colombia Nanoparticle Contract Manufacturing Services Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By Manufacturing Scale
      • 10.3.2.2.4. By End User
  • 10.3.3. Argentina Nanoparticle Contract Manufacturing Services Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By Manufacturing Scale
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Nanoparticle Contract Manufacturing Services Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Catalent
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Lonza
• 15.3. Evonik
• 15.4. Particle Sciences
• 15.5. Precision NanoSystems
• 15.6. CordenPharma
• 15.7. WuXi AppTec
• 15.8. Novasep
• 15.9. Formulaction
• 15.10. Curia

16. Strategic Recommendations

17. About Us & Disclaimer